GlobeNewswire Inc.··Not SpecifiedNeomorph Raises $100M Series B to Accelerate Molecular Glue Degrader Pipeline
Neomorph closes $100M Series B led by Deerfield Management to advance NEO-811, its molecular glue degrader for kidney cancer, and expand its pipeline.
REGNclinical trialbiotechnology